•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Carpenter Technology Corporation $CRS Stake Trimmed by Chicago Partners Investment Group LLC
Can Carpenter Technology Sustain Its Record Operating Income?
AMG TimesSquare Mid Cap Growth Fund Q3 2026 Portfolio Update
Carpenter Technology Corporation Announces Senior Leadership Appointments
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
Allspring Growth Fund Q3 2026 Performers And Detractors
Carpenter Tech: 3 Key Takeaways for Long-Term Investors
Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors
CRS Investors with $100,000 in Losses Have Opportunity to Join Carpenter Technology Corporation Fraud Investigation with SBS Law
Why Carpenter Technology (CRS) is a Top Growth Stock for the Long-Term
Carpenter: Buying The Dip, Clear Opportunity (Rating Upgrade)
CRS INVESTOR ALERT: Investigation of Carpenter Technology Corporation Announced by Holzer & Holzer, LLC
Why Carpenter Technology Stock Plunged 24.5% This Week
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
E. Ohman J or Asset Management AB Makes New $731,000 Investment in Carpenter Technology Corporation $CRS
CRS Q1 Earnings Call Highlights Aerospace Demand and Pricing Gains
Lost Money on Carpenter Technology Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 20.62% Share Price Drop
Lost Money on Carpenter Technology Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 20.62% Share Price Drop
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MS
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026